• Sudeep Bhardwaj Department of Pharmacology, Seth G. L Bihani S. D College of Technical Education, Sriganganagar, Rajasthan, India
  • Parveen P Balgir
  • Rajesh K Goel


Personalized medicine is a long-term vision, a formidable challenge, and will require varied approaches to achieve success. Concept of right medicine to the right individual at the right dose and at the right time is personalized medicine. Using the approach of personalized medicine and Knowledge of genetic factors that predict antihypertensive drug response may eventually enable clinicians to choose the most effective drug for each individual patient based on his or her genetic profile. This tailored therapy may help patients achieve better blood pressure control and may help to reduce the costs and adverse effects of antihypertensive therapy.

Kewwords: GWAS: genome-wide association study, SNP: single nucleotide polymorphisms, EMA: European medical agency.

Author Biography

Sudeep Bhardwaj, Department of Pharmacology, Seth G. L Bihani S. D College of Technical Education, Sriganganagar, Rajasthan, India
Professor, Department of pharmacology


1. Mahgoub A, Dring LG, Idle JR, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584–6,
2. Smith RL. Introduction: human genetic variations in oxidative drug metabolism. Xenobiotica 1986;16:361–5.
3. Marez D, Legrand M, Sabbagh N, Guidice JM Lo, Spire C, Lafitte JJ, et al. Olymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193–202.
4. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516–20.
5. Propping P, Nothen MM. Genetic variation of CNS receptors-a new perspective for pharmacogenetics. Pharmacogenetics 1995;5:318–25.
6. Kalow W, Staron N. On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. Can J Biochem Physiol 1957;35:1305–20.
7. Kalow W, Gunn DR. Some statistical data on atypical cholinesterase of human serum. Ann Hum Genet 1959;23:239–50.
8. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J 1960;2:485–91.
9. Lu AY. Drug-metabolism research challenges in the new millennium: individual Variability in drug therapy and drug safety. Drug Metab Dispos 1998;26:1217–22.
10. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356:1667–71.
11. Evans WE, McLeod HL. Pharmacogenomics–drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538–49.
12. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003a;348:529–37.
13. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004;429:464–8.
14. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006;57:119–37.
15. Lin JH. Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy. Curr Drug Metab 2007;8:109–36.
16. Lu ayh, Ma Q. Pharmacogenetics and individualized medicine, in ADME Enabling Technologies in Drug Design and Development (Zhang D, Surapaneni S eds). in press. Wiley & Sons, New York; 2010.
17. Altman RB. Pharmacogenomics: ‘noninferiority’ is sufficient for initial implementation. Clin Pharmacol Ther 2011;89(3):348–50.
18. Metzker ML. Sequencing technologies the next generation. Nat Rev Genet 2010;11(1):31–46.
19. Hawkins RD, Hon GC, Ren B. Next-generation genomics: an integrative approach. Nat Rev Genet 2010;11(7):476–86.
20. Hindorff LA, Sethupathy P, Junkins HA. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 2009;106(23):9362–7.
21. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–43.
22. Kruglyak L. Prospects for whole-genome linkage disequilibrium mapping of commondisease genes. Nat Genet 1999;22:139–44.
23. Ott J. Predicting the range of linkage disequilibrium. Proc Natl Acad Sci USA 2000;97:2–3.
24. Karnik AM. Update in pulmonary diseases. Ann Intern Med 1999;131:596–604.
25. Smith LJ. Newer asthma therapies. Ann Intern Med 1999;130:531–2.
26. Ruckdeschel JC. Update in oncology. Ann Intern Med 1999;131:760–7.
27. Antman KH, DF Heitjan, GN Hortobagyi. High-dose chemotherapy for breast cancer. JAMA 1999;282:1701–3.
28. Hoffman PC. Lung cancer. Lancet 2000;355:479–85.
29. Schneider RK, Levenson JL. Update in psychiatry. Ann Intern Med 1999;131:514–21.
30. Fredman, SJ Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current ‘‘next steps’’ practices. J Clin Psychiatry 2000;61:403–8.
31. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462–70.
32. Scott J. Treatment of chronic depression. N Engl J Med 2000;342:1518–20.
33. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281–303.
34. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754–8.
35. Furata T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hana H, et al. Effect of genetic differences in omeprazole metabolism on cure rates for helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129:1027.
36. Veterans administration cooperative study group on antihypertensive agents comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension, II: results of long-term therapy. JAMA 1982;248:2004-11.
37. Eckford PD, Li C, Ramjeesingh M, Bear CE. CFTR potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP independent manner. J Biol Chem 2012;287:36639-49.
38. Meyer UA, Zanger UM, Schwab M. Omics and drug response. Annu Rev Pharmacol Toxicol 2012; 53:475-502.
39. Turner ST, Bailey KR, Fridley BL. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 2008;52:359-65.
40. Haas M, Yilmaz N, Schmidt A. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian study group of the effects of enalapril treatment in proteinuric renal disease. Kidney Blood Press Res 1998;21:66-9.
41. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein β(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001;37:739-43.
42. Liu J, Liu ZQ, Yu BN. β1-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 2006;80:23-32.
43. Materson B, Reda D, Cushman W, Massie B, Freis E, Kochar M, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. New Engl J Med 1993;328:914-21.
44. Materson B, Reda D, Cushman W. Department of veterans affairs singledrug therapy of hypertension study. Revised fig. and new data. Am J Hypertens 1995;8:189-92.
45. Seedat Y. Varying responses to hypotensive agents in different racial groups: black versus white differences. J Hypertens 1989;7:515-8.
46. Weder A, Julius S. Pathophysiology of hypertension and treatment. In: Singh B, Vanhoutte P, Dzau V, Woosley R. editors. Cardiovascular pharmacology and therapeutics. New York: Churchill Livingstone Inc; 1994. p. 861-83.
47. Hall W. Pharmacologic therapy of hypertension in blacks. J Clin Hypertens 1987;3:108S-113S.
48. Kaplan N. Critical comments on recent literature age and the response to antihypertensive drugs. Am J Hypertens 1989;2:213-5.
49. Robertson J. Comparative studies in hypertension: some fallacious claims of age-related drug effcacy. J Hypertens 1990;8:S59-S61.
50. Vez L, La Vecchia L, Vincenzi M. Hypertension, obesity and response to antihypertensive treatment: results of a community survey. J Hum Hypertens 1992;6:215-20.
51. Hayes S, Taler S. Hypertension in women: current understanding of gender differences. Mayo Clin Proc 1998;73:157-65.
52. Buhler F, Bolli P, Kiowski W, Erne P, Hulthen U, Block L. Renin profling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med 1984;77:36-42.
53. Laragh J, Lamport B, Sealey J, Alderman M. Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 1988;12:223-6.
54. Blumenfeld J, Laragh J. Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens 1998;11:894-6.
55. Freis E, Materson B, Flamenbaum W. Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system. Am J Med 1983;74:1029-41.
56. Preston R, Materson B, Reda D, Williams D, Hamburger R, Cushman W, et al. Age-race subgroup compared with renin profle as predictors of blood pressure response to antihypertensive therapy. JAMA 1998;280:1168-72.
57. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-13.
58. Weber W. Pharmacogenetics. New York: Oxford University Press; 1997.
59. Luft FC. Molecular genetics of human hypertension. J Hypertens 1998;16:1871-8.
60. Donna K Arneet, Steven A Class, Stephen P Glasser. Pharmacogenetics of antihypertensive treatment. Vascular Pharmacol 2006;44:107-18.
61. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003;74:44-52.
62. O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond) 2000;99:233-8.
63. Karlsson J, Lind L, Hallberg P. Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol 2004;27:347-50.
64. Filigheddu F, Reid JE, Troffa C. Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade. Pharmacogenomics J 2004;4:154-60.
65. Sofowora GG, Dishy V, Muszkat M. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 2003;73:366-71.
66. Liu J, Liu ZQ, Tan ZR. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003;74:372-79.
67. Bruck H, Leineweber K, Temme T. The Arg 389 Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol 2005;46:2111-5.
68. Liggett SB, Mialet-Perez J, Thaneemit-Chen S. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 2006;103:11288–93.
69. Brodde OE. Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol Ther 2008;117:1-29.
70. Bengtsson K, Melander O, Orho-Melander M. Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation 2001;104:187-90.
71. Hahntow IN, Koopmans RP, Michel MC. The beta2-adrenoceptor gene and hypertension: is it the promoter or the coding region or neither? J Hypertens 2006;24:1003-7.
72. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. Seventh report of the joint national committee on prevention, Detection, Evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206– 52.
73. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, et al. Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997;349:1353-7.
74. Glorioso N, Manunta P, Filigheddu F, Troffa C, Stella P, Barlassina C, et al. The role of a adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999;34:649-54.
75. Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G, et al. ACE and alpha adducin polymorphism as markers of individual response to diuretic therapy, Hypertension 2003;41(3):398-404.
76. Maitland-van der Zee AH, Turner ST, Schwartz GL, Chapman AB, Klungel OH, Boerwinkle E. A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide. Pharmacogenet Genomics 2005;15:287-93.
77. Bianchi G, Tripodi G, Casari G, Salardi S, Barber B, Garcia R, et al. Two point mutations within the adducin gene are involved in blood pressure variation. Proc Natl Acad Sci 1994;91:3999-4003.
78. Tripodi G, Valtorta F, Torielli L, Chieregatti E, Salardi S, Trusolino S, et al. Hypertension-association point mutations in the adducin a and B subunits affect actin cytoskeleton and ion transport. J Clin Invest 1996;97:2815-22.
79. Manunta P, Barlassin C, Bianchi G. Adducin in essential hypertension FEBS Lett 1998;430:41-4.
80. Cody R, Laragh J, Case D, Atlas S. Renin system activity as a determinant of response to treatment in hypertension and heart failure. Hypertension 1983;5(Suppl III):36-42.
81. Muntzel M, Drueke T. A comprehensive review of the salt and blood pressure relationship. Am J Hypertens 1992;5:1S-42S.
82. Hingorani A, Jia H, Stevens P, Hopper R, Claire Dickerson J, Brown M. Renin-angiotensin system gene polymorphisms in¯uence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995;13:1602-9.
83. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 1996;14:259-62.
84. Moriyama T, Kitamura H, Ochi S, Izumi M, Yokoyama K, Yamauchi A, et al. Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J Am Soc Nephrol 1995;6:1674-8.
85. Sasaki M, Oki T, Iuchi A, Tabata T, Yamada H, Manabe K, et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic Filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 1996;14:1403-8.
86. Jia H, Hingorani A, Sharma P, Hopper R, Dickerson C, Trutwein D, et al. Association of the Gs gene with essential hypertension and response to B-blockade. Hypertension 1999;34:8-14.
87. Bremer T, Man A, Kask K, Diamond C. CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension. Pharmacogenomics 2006;7:271-9.
88. Lanfear DE, Jones PG, Marsh S. Beta2-adrenergic receptor genotype and survival among patients receiving betablocker therapy after an acute coronary syndrome. JAMA 2003;294:1526–33.
89. Shin J, Lobmeyer MT, Gong Y. Relation of beta(2)-Adrenoceptor Haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol 2007;99:250–5.
380 Views | 734 Downloads
How to Cite
Bhardwaj, S., Balgir, P. P., & Goel, R. K. (2015). PHARMACOGENOMICS AND PERSONALIZED MANAGEMENT OF HYPERTENSION. Journal of Critical Reviews, 2(2), 1-6. Retrieved from
Pharmaceutical Sciences